Among the numerous oncogenes involved in human cancers, KRAS represents the most studied and best characterized cancerrelated genes. Several therapeutic strategies targeting oncogenic KRAS (KRAS onc ) signaling pathways have been suggested, including the inhibition of synthetic lethal interactions, direct inhibition of KRAS onc itself, blockade of downstream KRAS onc effectors, prevention of post-translational KRAS onc modifications, inhibition of the induced stem cell-like program, targeting of metabolic peculiarities, stimulation of the immune system, inhibition of inflammation, blockade of upstream signaling pathways, targeted RNA replacement, and oncogene-induced senescence. Despite intensive and continuous efforts, KRAS onc remains an elusive target for cancer therapy. To highlight the progress to date, this review covers a collection of studies on therapeutic strategies for KRAS published from 1995 to date. An overview of the path of progress from earlier to more recent insights highlight novel opportunities for clinical development towards KRAS onc -signaling targeted therapeutics.
Introduction
KRAS is a small GDP/GTP-binding protein that transduce extracellular signals into intracellular responses. It cycles between an inactive, GDP-bound ("off") state and an active, GTP-bound ("on") state. This off/on cycle is tightly regulated by RAS-specific guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) 1 . In its active state, KRAS binds and activates various effector proteins function and thus regulate downstream signaling pathways (Figure 1) . The conserved GDP/GTP-binding (G) domain of KRAS contains two flexible regions, the switch regions 1 and 2, which provide a functional platform for the interaction with regulators and effectors [2] [3] [4] . The C-terminus of KRAS, which is highly variable among the RAS paralogs, is the site for posttranslational modifications and responsible for KRAS anchorage to the plasma membrane [5] [6] [7] .
Upstream signaling pathways of KRAS are activated by binding of ligands to their transmembrane receptors, mostly receptor tyrosine kinases, and recruitment of docking proteins, such as GRB2, in complex with RAS-specific GEFs, which facilitates KRAS activation (Figure 1) [8] [9] [10] . GTP-bound KRAS further transduces the signal to its downstream effectors and thus activates multiple signaling pathways [11] [12] [13] [14] [15] . Thereby, KRAS controls various cellular processes, including survival, growth, proliferation, differentiation, and apoptosis [16] [17] [18] .
With the discovery of the mutational activation of RAS genes in human cancers dating back to the 1960s, extensive studies have been conducted to understand the localization, regulation and signaling of RAS proteins with the ultimate goal of developing anti-RAS drugs for cancer treatment 3 . Somatic mutations, most frequently identified KRAS4B (oncogenic KRAS or KRAS onc ) (COSMIC), contribute to robust gain-of-function effects and to various types of cancers as well as leukemia and lymphoma tumors [19] [20] [21] [22] . Due to reduced GTP hydrolysis and resistance to GAPs 19, 20 , KRAS onc persist in a constitutive active state and thus, strongly contribute to neoplastic signal transduction 23 .
Despite intensive efforts on the understanding of the mechanisms of intracellular trafficking, regulation and signaling activity of RAS proteins, specific inhibition of oncogenic RAS has not been clinically established to date 3 . Among the RAS protein family, KRAS mutations are the most common oncogenic driver in many human cancers 4 . Additionally, KRAS onc is a strong predictive biomarker of resistance to anti-EGFR (Epidermal Growth Factor Receptor) treatment. Therefore, the prevalence of KRAS mutations in a number of human cancers and its inherent resistance to anti-EGFR targeting underscores the clinical relevance of targeting KRAS onc in cancer treatment 2, 24 .
Extensive research on different cell lines harboring the KRAS mutation have been conducted, including a pancreatic cancer cell line (PANC-1) 25 , human colorectal cancer cell lines (DLD-1, HCT-116, and Colo-320 cells) 26 , non-small cell lung cancer (H441 cells) 27 , human bronchial epithelial cells (HBEC3KT cells) 28 , human alveolar basal epithelial cells (A-549 cells) 29 , human oral squamous cell carcinoma (H157 cells) 29 , human breast adenocarcinoma cells (MCF-7 and SKBR3-LR cells) 30 , murine embryonic fibroblasts (MEFs) 31 , and acute myeloid leukemia cells (NOMO-1) 25 . According to studies on targeting the KRAS oncogene, therapeutic strategies can be divided into two main categories: 1) small molecule inhibitors, which are synthetically lethal to mutant KRAS or designed to prevent the post-translational processing of KRAS onc , upstream pathways, KRAS onc /GEF interactions and downstream KRAS * effectors; and 2) anti-KRAS genetic therapies, which interfere with the expression of KRAS or other components of KRAS onc -associated signaling pathways.
The complexity of KRAS signaling pathways, in which KRAS protein interacts with many different upstream mediators, downstream effectors, and transcription factors in a nonlinear fashion, has a critical role in the lack of effective treatment [32] [33] [34] . Thus, a better understanding of KRAS interactions with other proteins and transcription factors may provide new opportunities for effective treatment (Figure 1) . In this review, we provide a snapshot view of the rich history of KRAS research by chronologically discussing representative key retrospective discoveries regarding the various therapeutic options for cancers associated with KRAS mutations. In addition to basic original anti-KRAS onc therapeutic mechanisms, novel approaches, including inhibition of the embryonic stem cell-like program 18 , targeting of upstream tyrosine kinases 10 , stabilization of KRAS onc G-quadruplex structures 35 , inhibition of inflammation 36 , and targeting of metabolic peculiarities 37 , for suppression of aberrant KRAS activation in cancers are also explained (Figure 2) .
In addition to KRAS mutations, amplification of wild-type KRAS gene or EGFR mutation leads to the over-expression or over-activation of KRAS, respectively. Some studies have shown that both over-expressed KRAS and KRAS onc can be associated with aggressive and metastatic cancer phenotype 38, 39 . Regarding these similarities, some of the targeting strategies discussed in this review may be applied for both KRAS and KRAS onc , e.g., inhibition of downstream signaling pathways or inhibition of plasma membrane localization. In contrast, structural differences between KRAS onc and KRAS provide distinct therapeutic opportunities 40 . Some studies, which are referred to in this review, focus on total RAS proteins. Considering that the KRAS mutation represents approximately 90% of identified RAS mutations 33 , the results of studies on total RAS proteins could certainly be applied to KRAS protein. [41] [42] [43] . After translation of KRAS protein, it must undergo a series of post-translational modifications, which facilitate its association with the cell membrane. Initially, the enzyme farnesyl transferase (FTase) catalyzes the addition of a farnesyl isoprenoid moiety to the thiol group of the terminal cysteine in the CAAX motif of KRAS protein 44 . CAAX stands for C, a cysteine, A for aliphatic amino acids and X for any amino acid. Next, protease RASconverting enzyme-1 (RCE-1) cleaves the terminal AAX amino acids, and then the carboxyl group of the cysteine is methylated by isoprenyl-cysteine carboxymethyl transferase-1 (ICMT-1) 43,45,46 . Multistep post-translational modifications of KRAS protein provide several possible drug targets, including FTase, RCE-1, and ICMT-1 43,44 . Thus, attempts have been made to target KRAS post-translational modifications to inhibit its membrane localization and thus its activation and downstream signaling for the treatment of cancers. Prevention of KRAS onc processing to form a stable interaction with the cell membrane is not the only mechanism to reduce the population of KRAS onc at the membrane. Displacement of KRAS onc from the membrane and the impairment of proper trafficking are the two other strategies 47,48 . For instance, perturbation of the subcellular distribution of phosphatidylserine leads to a significant reduction of electrostatic interactions between KRAS onc and the plasma membrane, resulting in its displacement from the membrane. Another strategy triggering the mislocalization of KRAS onc is phosphorylation of S181 in the C-terminal hypervariable region (HVR) of KRAS onc , thereby activating the farnesyl-electrostatic switch.
Inhibition of KRAS localization

KRAS localization in the plasma membrane is a critical step
Targeting post-translational modifications of KRAS onc to inhibit its plasma membrane localization appeared to be promising in preclinical studies; however, alternative posttranslational modifications of KRAS onc and disruption of the prenylation of proteins other than KRAS onc have led to disappointing results. In spite of the earlier unsuccessful results, continuation of the studies on the disruption of KRAS onc plasma membrane localization has led to the development of novel treatment outcomes. For example, RAS binding proteins, such as phosphodiesterase delta subunit (PDEδ), have attracted considerable attention as a new target 42, 49 . Prenylation of KRAS increases its hydrophobicity and, thus, reduces its solubility. PDEδ facilitates the distribution of RAS family proteins by covering hydrophobic group. Therefore, inhibition of the RAS-PDEδ interaction prevents oncogenic RAS (RAS onc ) activation and signaling and results in an anti-cancer effects on RAS-transformed cells. In recent studies, blockade of the prenyl-binding pocket of PDEδ demonstrated promising result 42, 49 . In order to have a view on the progress has been made for disruption of KRAS onc plasma membrane localization, studies examining the blockade of KRAS onc processing, mislocalization, and trafficking published from 1993 to 2016 are summarized chronologically ( Table 1 ).
Direct inhibition of KRAS onc
In response to extracellular stimuli that activate cell surface receptors, RAS protein members mediate the transduction of extracellular signals to intracellular responses. Small GTPases of the RAS family function as molecular switches that cycle between active, GTP-bound and inactive, GDP-bound states 66 . Activation of upstream signaling pathways results in the recruitment of GEFs, such as SOS1 and SOS2, which facilitate KRAS activation by catalyzing the release of GDP from KRAS 67, 68 . Activated KRAS controls different cellular processes that are also involved in the transformation of normal cells to the malignant phenotype 69 .
The intrinsic GTPase activity of wild-type KRAS is enhanced by GAPs; however, oncogenic KRAS mutations lead to the impairment of GTP hydrolysis and cause GAP insensitivity and thus constitutive activation of KRAS onc70-73 . Indeed, inhibition of the constitutively active KRAS onc is a conceptually ideal strategy for cancer therapy. Two general mechanisms have been suggested for direct inhibition of RAS proteins, including decreasing the proportion of KRAS onc in its GTP state and disrupting the KRAS onc -effector interactions. To decrease KRAS onc -GTP levels, several approaches have been used, such as the inactivation of KRAS onc with small molecules or GTP analogs that facilitate GTP hydrolysis activity, interference with the nucleotide exchange process through disruption of the SOS-KRAS onc interaction, subversion of the native nucleotide preference of the KRAS onc to favor GDP over GTP, irreversible inhibition of the KRAS onc with its covalent modification, inactivation of KRAS onc in the GTP state, inhibition of intrinsic nucleotide exchange, and inhibition of nucleotide binding 40, 67, 74 .
Activation of downstream effectors, such as RAF kinases, is accomplished through direct interaction of KRAS onc with its effectors. Likewise, other approaches in treatment of KRAS onc -driven cancers, first generation of RAF kinase inhibitors had limited clinical benefit where the inhibitors found to paradoxically activate ERK pathway through the induction of RAF dimerization in RAS-mutant cancers 75 . Discovery programs in the development of new RAF Continued inhibitor compounds overcome limitations associated with RAF dimerization. Next generation inhibitors take two approaches to combat RAF dimerization. The first approach is the development of compounds with the equal potency for inhibition of both monomeric and dimeric RAF. The second strategy is the recruitment of ATP binding cleft to disrupt RAF dimerization 75 . Other than these therapeutic strategies, progress has been made in generating alternative agents to inhibit KRAS onc -RAF interaction which is needed to stimulate RAS-dependent oncogenic signaling 40, 76 . Thus, a better understanding of the detailed interactions of KRAS onc with RAS binding domains and RAS association domains of its downstream effectors provides alternative opportunities for the inhibition of intermolecular interactions 77, 78 . Table 2 provides a summary of studies examining the direct inhibition of KRAS mutant from 1997 to 2017. Direct inhibition of KRAS onc probably one of the most important therapeutic strategies, has some drawbacks. Direct targeting of this oncogene is difficult owing to its picomolar affinity for GTP/GDP. Furthermore, the interaction of KRAS with small molecules that facilitate GTP hydrolysis is challenging because the active site is occupied by guanine nucleotides, and there is little space for binding small molecules 94 . KRAS molecular switching and signaling are accomplished by protein-protein interactions. Inhibition of these interactions requires a detailed understanding of the interacting interfaces and their characteristics. Additionally, the relative featureless topologies of these surfaces and poor drug-like properties of peptides that disrupt protein-protein interactions make the inhibition more challenging 73 . While targeted therapy against many cancers, such as EGFRmutated cancers, provides effective responses, no FDAapproved KRAS onc -targeted therapy is currently available, and cytotoxic chemotherapy remains the best option for patients with KRAS onc -driven cancers. Hopefully, following the earlier failures in the direct inhibition of KRAS onc , a new wave of research in recent years has provided promising results. The KRAS oncoprotein has some specific structural features in comparison to wild-type KRAS. Selective targeting of these differences allows direct inhibition of the KRAS mutant without affecting wild type KRAS. For example, recent studies focusing on the KRAS-G12C mutation as a direct inhibition strategy have been showed significant results. In this type of mutation, the thiol group of the cysteine residue located close to the nucleotide-binding pocket, switch I, and switch II, are targeted by different small molecules that result in the inhibition of downstream interactions. Since KRAS-G12C is the most common mutation in lung cancer patients, the translation of this agent to clinical practice would be a significant approach for generating novel anti-KRAS onc therapeutics 40,67 .
RNA interference
The KRAS oncogene activates multiple downstream cellular pathways to drive the progression of cancer 1, 95 68 Continued the unsuccessful EGFR targeted therapy for KRAS oncdependent cancers and the difficulty associated with targeting KRAS onc directly, a great deal of effort has been applied to target downstream effector pathways. The specific interaction of RAS family proteins with downstream effectors regulates various cellular functions 3, 77, 96, 97 . Constitutive activation of downstream effector pathways by oncogenic KRAS results in the uncontrolled growth, proliferation, and survival of cancer cells 98 . It is essential to identify the effector pathways that are required for KRAS-driven carcinogenesis to identify pathways that should be targeted for treatment 99 . Two of the best-characterized KRAS effector pathways are the RAF-MEK-ERK and PI3K-AKT-mTOR pathways, which are integral to KRAS onc -driven transformation through different signaling cascades 100-102 . These pathways comprise different kinases, providing multiple nodes for potential therapeutic intervention 103, 104 . Collectively, studies on targeting the RAF-MEK-ERK and PI3K-AKT-mTOR pathways are divided into two categories. The first series of the studies focused on the identification of compounds Table 3) .
The results of these studies have shown that, due to the interplay between downstream signaling pathways of KRAS, inhibition of one downstream target leads to the overexpression of its interconnected pathways, creating a drug-resistant phenotype. For example, in response to MEK inhibition, PI3K is activated through a negative MEKepidermal growth factor receptor-PI3K feedback loop 32,112 . Therefore, novel therapeutic approaches are focusing on the disruption of these multiple nodes, which is only possible through the inhibition of multiple downstream kinases, rather than only one through combination therapy 100-104 ( Table 4 ).
According to the valuable results from the combination therapy, extensive studies are moving forward based on multi-targeted therapy for the inhibition of KRAS onc downstream signaling pathways. Recently, a large trial investigated the therapeutic effects of the MEK inhibitor selumetinib and docetaxel in comparison to docetaxel alone, producing results in NSCLC patients with the KRAS mutation 114 . Other results from an ongoing trial show a clinical benefit from combination therapy with an investigational MEK inhibitor known as PD-0325901 and palbociclib, an inhibitor of CDK4/6 (PD-0332991), in patients with KRAS-mutant NSCLC (NCT03170206) and KRAS-mutant PDAC (NCT03454035). In addition, phase II of the other ongoing study on investigational drugs GSK2256098 (focal adhesion kinase inhibitor) and trametinib (MEK inhibitor) was planned to evaluate the antitumor activity of this combination therapy in patients with advanced pancreatic cancer (NCT02428270). BVD-523, an ERK inhibitor, is also currently being tested in combination with nab-paclitaxel plus gemcitabine in a phase Ib trial in patients with metastatic pancreatic cancer (NCT02608229). Another downstream inhibitor is mTOR, a component of the PI3K pathway. The mTOR inhibitor (NCT02329717) PBI-05204 has been tested in patients with stage IV pancreatic cancer. In the other clinical trial, the pan-RAF inhibitor (LXH254) and ERK suppressor (LTT462) are being evaluated as combination therapy for patients with advanced-stage solid tumors with mitogen activated protein kinase (MAPK) alterations, including KRAS-mutant NSCLC (NCT02607813 and NCT02974725). Additionally, phase I/II trials have been initiated to assess the combination therapy of the MEK inhibitor trametinib and the BCL-XL and/or BCL-2 inhibitor navitoclax in patients with KRAS-mutant advanced-stage solid tumors (NCT02079740).
Response evaluation criteria in solid tumors
RNA interference (RNAi) is based on a natural process by which RNA molecules inhibit the generation of protein from DNA 115, 116 . For example, in the search for novel strategies in the treatment of KRAS onc -driven cancer, microRNAs (miRs) have received attention for their role in the regulation of gene 118, 119 . These molecules exert their action by binding to target mRNAs to prevent protein production. The degree and nature of the complementarity between the microRNA and target mRNA determines the gene silencing mechanism that will be employed. Perfect complementarity to the mRNA target leads to its subsequent degradation and transcriptional inhibition, while partial complementarity results in the blockade of translation 120 . Therefore, this complementarity plays a key role in regulating the target gene of a particular microRNA. For instance, polymorphisms of the let-7 microRNA binding site in the 3' untranslated region of KRAS leads to an impairment of their complementarity and elevated expression of KRAS 117, 121, 122 . The dysregulation of microRNAs and their critical roles in carcinogenesis results from the ability of microRNAs to control the expression of oncogenes and tumor suppressor genes 123 . For a microRNA with tumor-suppressor activity, its downregulation promotes tumorigenesis, while overexpression of a microRNAs with oncogenic effects leads to cancer development. Mechanisms responsible for the deregulation of miRs in cancers can be classified as genetic and epigenetic alterations that are observed in cancer cells 124 . Considering KRAS as a proto-oncogene, downregulation of miRNAs that suppress KRAS activation and activation of miRNAs that modulate KRAS expression can lead to cancer development 125 . Some of the microRNAs directly target KRAS, and some of them suppress KRAS activation through other targets ( Table 5 ). For example, the results of a study showed that KRAS onc suppresses mir-200 family expression through its downstream effectors JUN and SP-1 119 . An alternative RNA therapeutic approach to miRNAs is through the use of small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) from the family of non-coding RNAs 115 ( Table 5 ). SiRNAs also regulate gene expression through gene silencing with inhibition of gene translation into protein 126 . Additionally, their similarity in structural characteristics and pharmacokinetic profiles facilitates their use as therapeutics 127 .
Regarding RNA-mediated silencing method, there are two strategies to suppress KRAS oncogenic signaling. First strategy is direct in which KRAS gene expression is reduced by direct binding of RNAi to KRAS onc mRNA ( Table 5 ). Second approach is indirect, which is based on the inhibition of synthetic lethal interactions. Synthetic lethality is a phenomenon through which a genetic alteration leads to cell death only in the presence of another genetic perturbation. Mechanistically, synthetic lethal interactions can involve genes that are functionally connected 148 . In cancer cells, aside from pathways directly controlled by oncogenes, there are several non-oncogene-targeted pathways, which are involved in the process of transformation 149 . Thus, oncogenes require additional support from other genes to maintain the oncogenic state 26 . A major challenge in cancer treatment is the identification of targets that can be inhibited for the selective killing of cancer cells while sparing normal cells. Synthetic lethal interactions between oncogenes and non-oncogenes in cancer cells increase the sensitivity of cancer cells to selective therapeutics in comparison to normal cells 150 .
The KRAS mutation predisposes cancer cells to additional dependencies on the activity of genes that are not directly regulated by KRAS. This phenomenon can provide an approach for the selective treatment of KRAS onc -driven cancers according to the synthetic lethal interactions 26, 151 . The KRAS signaling pathway is complex, so several potential synthetic lethal targets are required for the initiation or maintenance of KRAS mutant tumors. To identify critical nodes in the signaling pathways regulating aberrant KRAS onc signaling, RNA silencing technologies could be exploited 152 . These newly identified synthetic lethal interactions lead to novel therapeutic opportunities. Additionally, small-molecule synthetic lethality screens have resulted in the identification of the selective effect against KRAS mutant cells compared with wild-type cells 31, 153 . It should be noted that inhibition of synthetic lethal interactions is not only accomplished by RNAi, but also with small molecules. A summary of researches on the screening of synthetic lethal interactions with KRAS onc through RNA silencing methods or small molecules is provided in Table 6 .
Antisense oligonucleotides directed against KRAS onc have indicated a therapeutic benefit in laboratory studies, opens up multiple effective possibilities for suppressing KRAS activity, and preventing the feedback response and drug resistance while facilitating combination therapy 99 . Despite the tremendous potential of RNA-based therapies, the successful application of this technology is currently limited. RNAs are inherently unstable, and therefore there is lack of efficient delivery of sufficient amounts to the target tissue. Additionally, toxicity due to off-target effects and the induction of immune system responses also represent difficulties related to this approach 115, 158, 159 .
Targeting the immune system
Cancer immunotherapy for patients carrying the KRAS mutation has become a clinical oncology reality. KRAS-G12D knockdown cells show increased production of interleukin 18 by the host immune system, leading to a dramatic reversion of the transformed phenotype and reduction of the proliferation rate of cancer cells 129 
. Increases in NK cells and
antibody-dependent cell-mediated toxicity after combination therapy with lenalidomide and cetuximab lead to increases in circulating naïve and central memory T cells in patients with
KRAS-mutant colorectal cancer 160 . The KRAS mutation induces increased expression of programmed cell death 1 ligand 1 (PD-L1) 161 . According to these findings, Ebert et al. showed that anti-PD-L1 antibodies significantly reduced tumor size in MEK inhibitor-treated mice with the KRAS mutation. Thus, it seems that the combination of immunotherapy and anti-proliferative agents, such as MEK inhibitors, provides higher anti-tumor activity 162 . Genetic alterations are specific to cancer cells and are not present in normal cells; thus, treatments that specifically target the protein product of these genetic aberrations may provide a clinical benefit in the absence of normal cell toxicities. Although mutant KRAS proteins themselves are not strongly immunogenic, efforts are underway to enhance the ability of the immune system to recognize KRAS mutant peptides as neo-epitopes. For example, specific immunogenic mutations could help to recognize KRAS mutant variant peptides of the most frequent KRAS mutations, such as G12V and G12D, by specific T cell receptors 163 . In this way, to develop more effective personalized immuno-therapy for patients with the KRAS mutation, Rosenberg's team isolated tumor-infiltrating lymphocytes (TILs) with the ability to specifically target the KRAS mutation. The findings of that study, which were presented in December 2016, introduced, for the first time, a novel immunotherapy-based strategy, called adoptive T cell transfer immunotherapy. These results validated the possibility of using personalized T cell receptor gene therapy against multiple types of cancer expressing this common mutation or other types of KRAS mutations 163 . Thus, the purpose of recent studies has been the identification of immune-editing of T cells during tumor development, as well as the determination of their potential applications for tumor-specific immunotherapy 164 .
According to the brilliant results from immunotherapy, treatments focused on altering the immune system for patients suffering from KRAS onc -driven cancers have been intensively investigated in recent years, with new achievements. In one study, the efficacy of immune checkpoint inhibitors among NSCLCL patients was found to correlate with the KRAS mutation as a molecular smoking signature 165 . Other evidence indicates that the co-mutation of TP53 and KRAS in lung adenocarcinoma can be exploited as a potential predictive marker for effective immune checkpoint blockade immunotherapy 164 . Clinical trials have also been initiated for the KRAS-G12D-specific cancer vaccine TG01/ GM-CSF either alone or combined with gemcitabine. The initial results of these trials have shown an induction of the immune responses in response to TG01/GM-CSF plus gemcitabine combination therapy 166 . A study to evaluate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy versus regorafenib in participants with metastatic colorectal adenocarcinoma is currently ongoing as a phase III trial (NCT02788279). The initial findings suggest that this therapeutic strategy is helpful in improving the immune response. One trial examining the combination therapy of a newer CDK4/6 inhibitor, abemaciclib, with the immune checkpoint inhibitor pembrolizumab is currently ongoing in NSCLC patients with the KRAS mutation 167 . New achievements have been observed in these studies against human cancers ( Table 7) , represent the need for further studies to enhance immunotherapeutic efficacy in some patients.
Other approaches
Despite important strides made in the development of targeted therapy for KRAS onc -mediated cancers, no therapeutic approaches are clinically available. In recent years, a deeper understanding of the critical parameters involved in the promotion of KRAS onc -driven tumorigenesis has been considered for the development of new therapeutic options. In this part of the article, we review these new achievements and discuss multiple lines of evidence of novel key pathways that are recognized to interact with other previously identified KRAS-regulated survival pathways to transduce signals of carcinogenesis. The data suggest that cotargeting of these newly and previously recognized KRAS oncregulated pathways has significant clinical potential.
Inhibition of stem cell program
Cancer stem cells (CSCs) are defined as tumor-initiating cells with self-renewal capacity. They are considered to be responsible for cancer initiation, progression, metastasis, drug resistance, and treatment relapse 168 . The KRAS mutation has been shown to preferentially alter the profile of gene expression to induce embryonic stem cell-like features 169 . For example, the expression of some genes is known to be upregulated in the presence of the KRAS mutation, including fibroblast growth factor receptor 1 (FGFR1), which plays a common role in both embryonic and cancer development, LCK, the transcriptional silencing of which is required for embryonic stem cell differentiation, and the induced-pluripotency factor SOX2, which reprograms differentiated cells to pluripotency. In contrast, KLF4 expression was suppressed in KRAS mutant colon cancer cells, which is consistent with its induction of multiple cell lineage differentiation in the intestine 18 . Additionally, a KRAS-centric mechanism would apply in the context of epidermal-mesenchymal transition (EMT) to generate CSCs through the WNT pathway 170 .
Other results have indicated that oncogenic KRAS activation in the genetic background of loss-of-function of adenomatous polyposis coli (APC) results in enhanced CSC activation by increasing both intracellular stabilization of βcatenin and the MAPK pathway 171, 172 . Furthermore, endodermal progenitors expressing KRAS-G12V do not differentiate upon retinoic acid treatment and continue to proliferate and maintain stem cell characteristics 173 . Several studies have described the KRAS mutation as a driver of stem cell-like properties of cancer cells. Thus, inhibition of multiple key pathways involved in embryonic stem cell signaling represents a novel therapeutic strategy. Le Rolle et al. 18 showed that inhibition of KRAS mutant colon tumors with miR145, an epigenetic regulator and an embryonic stem cell inhibitor, suppressed their malignant growth. Data suggest that salinomycin, the most potent cancer stem cell inhibitor with potential efficacy in human cancers, specifically disrupts KRAS onc nanoscale membrane organization, effectively reducing effector recruitment to KRAS onc , which then compromised at least MAPK signaling and proliferation 170 . Ophiobolin A, another candidate CSC drug, has been found to possess higher potency than salinomycin and exert its KRAS4B-specific activity through the inactivation of calmodulin 170 .
Based on the role of the KRAS onc in stemness, α-Mangostin-encapsulated PLGA [poly (D, L-lactic-co-glycolic acid)] nanoparticles show inhibitory effects on carcinogenesis in transgenic mice carrying the KRAS mutant allele through the downregulation of pluripotency maintenance factors (c-MYC, NANOG and OCT4) and stem cell markers (CD24 and CD133) 174 . Overall, these data suggest that targeting multiple signaling pathways of cancer stem cell activation induced by the KRAS mutation could be an attractive therapeutic approach.
Targeting receptor tyrosine kinases (RTKs)
A growing body of evidence suggests that the KRAS mutation may serve as a predictive resistance marker to guide the use of anti-EGFR therapy. Multiple studies have demonstrated that patients with mutations in KRAS do not appear to experience a clinical benefit from anti-EGFR monoclonal antibody treatment 175 . In cancers with KRAS mutations, part of the cell survival and proliferation pathways could still be due to the activation of upstream RTKs other than EGFRs. Therefore, another possible approach to target tumors with KRAS mutations is through the inhibition of such critical RTKs that contribute to the enhanced prosurvival. The type 1 insulin-like growth factor receptor is a promising target in different types of cancers, including colon cancer 176 . The PI3K signaling pathway is a common downstream effector of both IGF-1R and KRAS. Thus, blockade of IGF-1R using different monoclonal antibodies or tyrosine kinase inhibitors is theoretically relevant for the treatment of patients with KRAS onc -driven cancers 8 . Although patients with the KRAS mutation show resistance to EGFR-targeted therapy, preclinical data have indicated that combination therapy with IGF-1R and EGFR kinase inhibitors results in synergistic growth inhibition in colorectal cancer cell lines 9 . Hurwitz et al. 10 showed a clinical benefit following the treatment of patients with bevacizumab as an anti-vascular endothelial growth factor (VEGF) therapy. Data have also shown that, unlike anti-EGFR therapy, anti-VEGF therapy functions independently of the KRAS mutation status, revealing even greater clinical significance.
Stabilization of the G-quadraplex
G-quadruplexes (G4) are special secondary structures containing runs of guanines separated by other bases 177 . The localization of G4 in the human genome was found to be non-random, indicating their important role in the regulation of functional regions. Significantly, G4 are more frequent in oncogenes or regulatory genes than in housekeeping or tumor suppressor genes. Their higher distribution in the promotors of oncogenes suggests a possible involvement of G4 in cancer 178 . Genome-wide analysis of human cells has revealed the role of these structures is genesilencing through the inhibition of replication, transcription, and translation 35 . Therefore, the stabilization of guanine-rich regions located in the oncogene promoters represents a highly valuable new molecular target for the development of novel anti-cancer therapeutics 177 . It is now evident that the core promoter region of KRAS contains silencing G4 elements 179 . G-to-T knockout mutations in the G4-forming regions of the KRAS promoter were found to disrupt or abrogate G4 formation. In addition, stabilization of the KRAS promoter by the cationic porphyrin TMPyP4 leads to a significant decrease in KRAS expression 180 . The interaction of G4 of the KRAS promoter with natural polyphenols, such as ellagic acid and curcumin, has also been confirmed by UVvis spectroscopy. Significantly, the melting temperature of the G-quadruplex is increased, indicating its stabilization upon interaction with polyphenol ligands 35 .
Inhibition of inflammation
KRAS-driven tumorigenesis is tightly connected with tumorpromoting inflammation, which increasingly represents another promising therapeutic strategy 181 . According to recent clinical data indicating the role of inflammation in the carcinogenesis related to the KRAS mutation, targeting inflammatory signaling pathways seems to be an essential component of therapy for tumors with KRAS mutations 182 . Different cellular pathways, which are modulated by KRAS and induce inflammation, include JAK/STAT, NF-κB, MAPK, and immune checkpoint signaling pathways 36 . For example, the KRAS mutation contributes persistent pancreatitis induced by cerulein. In this situation, suppression of inflammation by deletion of IKK-β and inhibition of NF-κB activity interferes with dysplasia. In contrast, overexpression of IKK-β cooperates with the KRAS mutant allele to promote oncogenesis 183 .
A different study indicated that while persistent KRAS activation drives the secretion of STAT3 pathway mediators, activation of STAT3 results in the amplification of KRAS onc carcinogenesis through the upregulation of anti-apoptotic and pro-proliferative proteins 184 . Co-administration of azoxymethane (AOM) and dextran sodium sulfate (DSS), respectively, as carcinogenic and inflammatory agents, results in a significant decrease in the latency of KRAS onc -driven tumor formation 185 . Given the presence of inflammatory stimuli in a KRAS mutation background as positive feedback promoting KRAS onc -associated carcinogenesis, targeting each of the mentioned signaling pathways would likely lead to the development of a mechanism for disease control.
Targeting metabolic pathways
Metabolic reprogramming of cancer cells due to oncogenic mutations is critical for cell growth and survival. Data show that the KRAS oncoprotein confers metabolic robustness for the acquisition of cellular metabolism networks to convert carbon sources into biomass 186 . The metabolic features of KRAS onc -driven cancers can be explained through the reprogramming of glucose, amino acids, and lipid metabolisms 37 . Cancer cells harboring KRAS onc promote the glycolytic switch, glucose uptake, increased channeling of glucose-derived metabolites into the tricarboxylic acid cycle, and activation of glucose-dependent biosynthetic pathways 187 . For example, it has been reported that the KRAS mutation increases the expression of glucose transporter-1 (GLUT1) and several rate-limiting glycolytic enzymes 188 . Interestingly, the induction of metabolic changes is dependent on the content of the KRAS mutant allele of cancer cells. Thus, glycolytic gene expression was markedly enhanced in KRAS-G12D/G12D relative to heterozygous lung tumor cells 187 . One mechanism by which KRAS onc aberrantly regulates metabolic networks is through the reprogramming lipid metabolism by the promotion of cellular uptake, retention, accumulation, synthesis, and oxidation of fatty acids. For instance, lung cancer cells carrying the KRAS mutation are highly dependent on the activity of acyl-coenzyme A synthetase long-chain family member 3 (ACSL3) 28, 189 . Mutated KRAS promotes lipogenesis through the induction of fatty acid synthase, leading to lipid signatures of human lung cancer cell lines 189 .
Other results have shown that the RAS mutation leads to the reprogramming of de novo lipogenesis of cancer cells by scavenging serum fatty acids 190 . Emerging evidence from different research groups indicates that KRAS mutations are associated with changes in amino acid metabolism 191 . Reprogramming of glutamine metabolism in KRAS onc -driven cancers is the most important alteration in amino acid metabolism. While most cells utilize glutamate dehydrogenase 1 for conversion of glutamate into αketoglutarate, cancer cells carrying the KRAS mutation convert glutamate to aspartate 191 . The increased requirement for branched-chain amino acids (BCAAs) is a very early phenomenon during tumor development, similar to some types of KRAS onc -driven cancers 192 . As mitochondrial activity is required for metabolic changes in cancer cells, autophagy as a mechanism for the elimination of defective mitochondria is crucial for tumor growth. Loss of essential autophagy genes in KRAS onc -driven cancer impairs effective mitochondrial function and suppresses tumor progression, emphasizing the role of autophagy in the intracellular nutrient supply 193 . These reports indicate that the KRAS mutation creates unique metabolic dependencies that could be exploited for anti-cancer therapy.
Targeted RNA replacement
Tetra hymena group I intron-based trans-splicing ribozyme is specific therapeutic tool with ability to discriminate the target RNA resulting in specific and high-fidelity cleavage reaction of its target 194 . Moreover, ribozymes can specifically transfer the therapeutic gene into cancer cells expressing target RNA. This specific trans-splicing reaction with the ability of discrimination target RNA from non-target one, even with a single nucleotide difference, makes it as an attractive novel treatment strategy for KRAS point mutations.
Regarding KRAS-G12V mutation as one of the most prevalent point mutation, Tetra hymena group I intronbased trans-splicing ribozyme designed for selective cleavage of KRAS-G12V transcript 195 . An accurate and specific intracellular trans-splicing reaction of the designed ribozyme systems with the KRAS-G12V target RNA, leads to efficient reduction of transcript level. Except that replacement of RNA, concurrent induction of suicide gene activity resulting in cytotoxicity and effective retardation of cancer cells harboring KRAS mutation 196 . Moreover, trans-splicing and therapeutic anti-cancer gene activity was selectively and efficiently induced only in KRAS-mutant cancer cells without targeting of cells expressing wild-type KRAS 195 .
Oncogene-induced senescence
Oncogene-induced cellular senescence (OIS) is a complex mechanism of tumor suppression which is thought to be triggered by aberrant activation of oncogenic signaling 197 . Undisputed role of RAS onc in different human cancers, necessitate studies on the RAS onc -induced senescence as an alternative treatment strategy. Senescence is not a simple mechanism triggered by only linear series of events and multiple components are required to establish a senescence response. Accordingly, detailed molecular mechanisms underlying OIS should be completely understood to provide adequate mechanistic insight for implementation of RAS aberrant oncogenic signaling against themselves as a potential anti-cancer strategy 198 .
Basically, there are three pathways which are recruited by KRAS onc to induce senescence which are also interconnected. The first pathway is transcriptional repression of proproliferative genes like E2F target genes. In addition to the transcriptional repression, a second pathway that is believed to mediate KRAS onc -induced senescence is the DNA damage pathway. Oncogene activation induces aberrant DNA replication events, leading to replication stress and subsequent DNA damage 198 . Consequently, DNA damage and accumulation of proteins involved in DNA damage response, like ATM and CHK2 results in senescence induced by oncogene activation. Finally, a third pathway, which is essential for senescence and recruited under RAS activation is senescence-associated secretory phenotype (SASP). Studies have recognized that SASP mediates RAS onc -induced senescence, through the secretion of specific proteins like C/EBPβ transcription factor 199 . Notably, the neurofibromatosis type 1 (NF1), encoding a RAS-specific GAP, has been implicated in OIS 200 . In this context, suppression of Ras and/or PI3K are sufficient to induce senescence, and these events on their own can activate the known downstream mediators of the senescence response (Rb and p53) through a variety of mechanisms 200 (Figure 1) . Moreover, in BRAF-driven melanomagenesis, loss of NF1 cooperates with RAF mutations by increasing PI3K/AKT signaling and preventing entry into OIS 201, 202 . While the significant role of the oncogenic RAS in human cancers has been proved for many years, a better understanding of the molecular basis of RAS onc -mediated senescence, allows the delineation of new therapeutic approaches surprisingly aimed at engagement of oncogenic signaling against oncogenic signaling.
Conclusions
More than 30 years of intensive research and tens of thousands of published studies have provided valuable insights into the biology, biochemistry and biophysics of RAS family proteins. Signal transduction of RAS (most notably KRAS) is regulated by three classes of canonical interacting partners, including regulators that control activation of the GTPase cycle (by GEFs), its inactivation (by GAPs), and a wide spectrum of effectors (e.g., RAF kinase and PI3 kinase) that initiate signaling cascades downstream of RAS and RASlike proteins. We have gained deep knowledge about their membrane trafficking, structure-function relationship, mechanisms of GDP/GTP binding and accelerated nucleotide exchange by GEFs, intrinsic and GAP-stimulated GTP hydrolysis, interaction with effectors and activation of diverse signaling pathways. However, these studies have their own eligibility confinement: cell-free investigations have been predominantly carried out in the absence of lipid membrane, using defined domains rather than full-length proteins, and cell-based studies have mostly been performed via the heterologous expression of tagged genes and their variants in methodologically congenial cell lines. As the omics era is coming to an end and research has decelerated, many new movements have emerged, especially due to the accessibility of new technologies. Several novel mechanisms have been uncovered that have extended our understanding of the role of protein-protein/protein-lipid interactions and various types of post-translational modifications in the modulation of RAS protein activity. Another issue is the activation mechanism of regulators and effectors. Notably, the identification of additional components of the RAS interaction networks is a critical step towards understanding both the relationship between RAS proteins and the selective activation of respective effectors, as well as the molecular signatures required for the spatiotemporal integration and activation of GEFs and GAPs. The identification and functional reconstitution of specific interaction networks by using appropriate liposomes and full-length effector proteins may eventually provide fundamental insights into the functional characterization of multiprotein complexes of RAS and the complete identification of regulatory mechanisms. In this context, an interesting issue, which is increasingly appreciated, is a RAS-membrane interaction that appears to generate RAS isoform specificity with respect to regulator and effector interactions. Currently, it has become more evident that an increasing number of additional RAS binding partners are critical in modulating and integrating RAS in various signaling networks at biological membranes. This phenomenon is likely achieved by scaffold proteins, including CAM, GAL1, GAL3, IQGAP1, NCL, NPM1, SHOC2, SPRY, SPRED1 and GAB1, which may modulate isoform specificity at specific sites of the cell. However, the roles of these additional RAS interaction proteins as novel modulators of RAS signaling remain unclear. Hence, elucidation of the RAS signal transduction requires not only RAS-effector interactions but also additional structures and the interplay of multi-protein complexes. Keeping this in mind, accumulating evidence supports a role for cell typedependent RAS paralog functions that should prompt future efforts to examine the respective pathways in a more contextspecific manner. Excluding driver mutations, passenger mutations accumulate and frequently escape natural negative selection, resulting in several oncological outcomes 203 . In parallel with standard tumor profiling methods, highthroughput technologies, such as next-generation sequencing, have been employed to shift the treatment paradigms. Thus, further characterization of the heterogeneous identity of patient tumor tissue exploring all specific molecular aberrations along with the specific KRAS mutation, seems to be critical for an effective therapy 204, 205 . Such efforts could lead to the identification of diseasespecific therapeutic opportunities. The other novel technology is phosphoprotein analysis through kinome profiling, which provides evidence of signaling pathways that are activated in a patient's tumor 206 .
The authors of this review article conclude that translating our knowledge of different treatment frameworks to the clinic via targeted therapy of the KRAS onc and personalized immune-therapy may be the best strategies to dramatically improve patient outcomes. In summary, we are at the beginning of a new series of attempts to treat KRAS onc -driven cancers by directly targeting the protein or through personalized targeted therapy with high-throughput or immunotherapy-based strategies. This new wave of personalized studies provide hope for thousands of patients suffering from KRAS onc -driven cancers. 
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